News

Video

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

Author(s):

Ulka Vaishampayan, MD,Laurence Albiges, MD, PhD

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

Related Videos
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Shubham Pant, MD, MBBS
Tiago Biachi, MD, PhD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Chelsey Schlechter, MPH, PhD
November 27th 2024

Dr Schlechter Named Cancer Moonshot Scholar

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs | Image Credit: © Katsyarina - stock.adobe.com
November 22nd 2024

NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs

Sandy Srinivas, MD, of Stanford Medicine
November 21st 2024

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents